| Literature DB >> 32231584 |
Yue Zhang1,2,3, Vicky Y Wang1,2,3, Ashley E Morgan2, Jiwon Kim4, Liang Ge1,2,3, Julius M Guccione1,2,3, Jonathan W Weinsaft4, Mark B Ratcliffe1,2,3.
Abstract
BACKGROUND: Functional Mitral Regurgitation (FMR) associated with coronary artery disease affects nearly 3 million patients in the United States. Both myocardial infarction (MI) and ischemia contribute to FMR development but uncertainty as to which patients will respond to revascularization (REVASC) of ischemia alone prevents rational decision making about FMR therapy. The aim of this study was to create patient-specific cardiac MRI (CMR) informed finite element (FE) models of the left ventricle (LV), calculate regional LV systolic contractility and then use optimized systolic material properties to simulate the effect of revascularization (virtual REVASC).Entities:
Keywords: computer simulation; coronary artery bypass; coronary artery disease; inverse finite element analysis; mitral valve insufficiency; myocardial infarction; myocardial ischemia
Year: 2020 PMID: 32231584 PMCID: PMC7082816 DOI: 10.3389/fphys.2020.00158
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.566
FIGURE 1Flowchart of the proposed method. Note that the raw data are in yellow, the derived pressure in blue, the CMR-derived geometry and strains in green, and the FE modeling process in gray.
FIGURE 2Examples of the 4 CMR image sequences used in this study: (A) Short axis Cine-CMR with LV epicardial and endocardial and RV endocardial contours; (B) A stress perfusion image with arrows indicating the ischemic region; (C) A late gadolinium enhancement (LGE-CMR) image with red arrows indicating the infarcted region, and (D) A short axis tagged (CSPAMM) image.
FIGURE 3(A) RV endocardial surface (triangle mesh), LV epicardial surface (hexahedral mesh), and the septum (in green) determined using a ray-casting method; (B) the final 17 sector FE model with the septal sectors in green.
Patient-specific LV and RV pressures and LV ejection fraction (EF).
| LV EDP [mmHg] | 20 | 20 | 20 | 20 | 10 | 10 |
| LV ESP [mmHg] | 121 | 140 | 100 | 134 | 140 | 120 |
| RV EDP [mmHg] | 3 | 8 | 8 | 3 | 8 | 8 |
| RV ESP [mmHg] | 23 | 28 | 23 | 20 | 40 | 25 |
| Ejection fraction (%) | 36 | 31 | 15 | 43 | 45 | 58 |
Patient-specific LGE and SP scores at baseline (BL), and wall motion (WM) scores at BL and follow up (FU) studies.
| Patient 1 | LGE score (BL) | 0 | 0 | 0 | 3 | 1 | 1 | 0 | 0 | 0 | 3 | 4 | 2 | 0 | 0 | 0 | 0 | 0 |
| SP score (BL) | 2 | 1 | 0 | 2 | 2 | 2 | 1 | 0 | 0 | 2 | 2 | 2 | 0 | 3 | 3 | 0 | 3 | |
| WM score (BL) | 1 | 1 | 1 | 3 | 4 | 3 | 1 | 1 | 1 | 3 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | |
| WM score (FU) | 0 | 0 | 2 | 2 | 3 | 1 | 0 | 0 | 1 | 3 | 4 | 1 | 0 | 0 | 0 | 1 | 0 | |
| Patient 2 | LGE score (BL) | 0 | 0 | 0 | 0 | 3 | 0 | 1 | 0 | 0 | 1 | 3 | 1 | 1 | 0 | 0 | 0 | 0 |
| SP score (BL) | 0 | 0 | 2 | 3 | 3 | 1 | 2 | 1 | 1 | 2 | 2 | 1 | 3 | 1 | 2 | 0 | 0 | |
| WM score (BL) | 0 | 0 | 1 | 3 | 4 | 1 | 3 | 0 | 0 | 3 | 3 | 1 | 3 | 0 | 3 | 1 | 3 | |
| WM score (FU) | 0 | 0 | 1 | 2 | 2 | 1 | 1 | 0 | 0 | 2 | 1 | 1 | 2 | 0 | 1 | 1 | 2 | |
| Patient 3 | LGE score (BL) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| SP score (BL) | 0 | 0 | 1 | 2 | 2 | 2 | 1 | 0 | 0 | 2 | 2 | 0 | 0 | 0 | 2 | 0 | 0 | |
| WM score (BL) | 3 | 3 | 3 | 4 | 3 | 3 | 3 | 3 | 3 | 4 | 3 | 3 | 3 | 3 | 4 | 3 | 3 | |
| WM score (FU) | 2 | 2 | 2 | 3 | 3 | 2 | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | |
| Patient 4 | LGE score (BL) | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 3 |
| SP score (BL) | 0 | 1 | 0 | 0 | 0 | 0 | 3 | 3 | 0 | 0 | 0 | 0 | 3 | 3 | 2 | 0 | 3 | |
| WM score (BL) | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 1 | 0 | 4 | |
| WM score (FU) | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 2 | 2 | 1 | 0 | 4 | |
| Patient 5 | LGE score (BL) | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 1 | 4 | 0 | 1 | 0 | 0 | 3 | 0 |
| SP score (BL) | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | |
| WM score (BL) | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 1 | 3 | 1 | 0 | 0 | 1 | 3 | 0 | |
| WM score (FU) | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 1 | 3 | 1 | 0 | 0 | 1 | 3 | 0 | |
Mesh convergence study.
| Patient 1 | 7952 | 0.099 | 523.3 | 1.0 | 137.3 |
| Patient 2 | 2700 | 0.207 | 322.7 | 0.32 | 48.0 |
| 4176 | 0.207 | 338.9 | 0.4 | 77.5 | |
| 7952 | 0.192 | 336.8 | 0.44 | 175.0 | |
| 10752 | 0.192 | 330.7 | 0.44 | 250.0 | |
| Patient 3 | 7952 | 1.7 | 173.5 | 0.08 | 599.4 |
| Patient 4 | 7952 | 0.019 | 227.9 | 0 | 462.3 |
| Patient 5 | 2700 | 0.0095 | 405.3 | 0.0 | 77.5 |
| 4176 | 0.0095 | 414.8 | 0.0 | 125.0 | |
| 7952 | 0.0094 | 401.4 | 0.0 | 400.0 | |
| 10752 | 0.0090 | 408.6 | 0.0 | 560.0 | |
| Volunteer | 7952 | 0.00011 | 259.4 | N/A | 1741.5 |
FIGURE 4Comparison of synthetic E with FE model predicted strain in patients 2 and 5.
Results of testing with synthetic data.
| Patient 2 | 336.8 | 0.0 | 100.0 | 0.0 | 336.7 | 0.0 |
| 350.0 | 0.5 | 337.6 | 0.0 | |||
| 600.0 | 1.0 | 336.7 | 0.0 | |||
| Patient 2 | 336.8 | 1.0 | 100.0 | 0.0 | 332.3 | 1.0 |
| 350.0 | 0.5 | 332.2 | 1.0 | |||
| 600.0 | 1.0 | 332.6 | 1.0 | |||
| Patient 5 | 401.4 | 0.0 | 350.0 | 0.5 | 401.5 | 0.0 |
| Patient 5 | 401.4 | 1.0 | 350.0 | 0.5 | 401.0 | 1.0 |
CMR-based in vivo volumes and the FE-predicted volumes after optimization.
| Patient 1 | 245.4 | 157.0 | 245.4 | 158.3 |
| Patient 2 | 160.9 | 111.0 | 160.9 | 108.3 |
| Patient 3 | 300.0 | 255.5 | 300.0 | 249.2 |
| Patient 4 | 170.0 | 97.4 | 170.0 | 96.5 |
| Patient 5 | 94.9 | 52.2 | 94.9 | 51.3 |
| Volunteer | 118.7 | 49.7 | 118.7 | 48.6 |
FIGURE 5(A) Optimization history of the overall objective function, and (B) surface plot of mean-squared-error of strain with respect to Tmax and α.
FIGURE 6The convergence of the parameter (lines in blue represent the upper and lower bounds) for (A) Tmax for healthy myocardium, and (B) ischemia effect, α, on the LV myocardial contractility, with each parameter resulted in a precise final converged optimum.
FIGURE 7Comparison of sector-specific CSPAMM and FE model predicted E across all 6 subjects. E derived from CSPAMM and calculated from FE simulations are in gray and red bars, respectively. The average sector specific MI/fibrosis (LGE) and stress perfusion (SP) scores are in yellow circle and blue diamond, respectively.
FIGURE 8Comparison of the sector specific E before and after virtual REVASC for the 3 patients with positive ischemia effect, α. Sector specific MI/fibrosis (LGE) and stress perfusion (SP) scores are plotted for reference. E BL represents E calculated using the FE simulations at baseline, E VR is the E obtained from the FE simulations after virtual REVASC, and E WM is an “actual” E effect estimated using the qualitative wall thickening scores.